for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amarin Corporation plc (ADR)

AMRN.OQ

Latest Trade

5.03USD

Change

-0.12(-2.33%)

Volume

771,358

Today's Range

5.00

 - 

5.25

52 Week Range

3.36

 - 

26.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Amarin Q2 GAAP Earnings Per Share $0.01

Aug 4 (Reuters) - Amarin Corporation PLC <AMRN.O>::REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q2 GAAP EARNINGS PER SHARE $0.01.Q2 REVENUE $135.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $149.5 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.CORPORATION PLC - VASCEPA CLINICAL TRIAL RESULTS ON-TRACK TO BE REPORTED BY AMARIN'S PARTNER IN CHINA BEFORE END OF 2020.CORPORATION PLC - AS OF JUNE 30, 2020, AMARIN REPORTED TOTAL CASH AND INVESTMENTS OF $611.3 MILLION.

HLS Therapeutics Inc - Reaffirms Peak-Year Sales Forecast For Vascepa

July 20 (Reuters) - HLS Therapeutics Inc <HLS.TO>::HLS THERAPEUTICS INC - REAFFIRMS ITS PEAK-YEAR SALES FORECAST FOR VASCEPA.HLS THERAPEUTICS INC - CADTH RECOMMENDS VASCEPA BE REIMBURSED FOR PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE UNDER CERTAIN CONDITIONS.HLS THERAPEUTICS INC - PMPRB NOTIFIES HLS THAT VASCEPA'S INTRODUCTORY PRICE SUBMISSION DID NOT TRIGGER PRICING INVESTIGATION CRITERIA.

Amarin Says Vascepa Shows Significant Cardiovascular Risk Reduction In People With Diabetes

June 15 (Reuters) - Amarin Corporation PLC <AMRN.O>::VASCEPA® (ICOSAPENT ETHYL) SHOWS SIGNIFICANT CARDIOVASCULAR RISK REDUCTION IN PEOPLE WITH DIABETES IN PRESPECIFIED AND POST HOC SUBGROUP ANALYSES OF LANDMARK REDUCE-IT® STUDY.AMARIN CORPORATION PLC - KEY SECONDARY COMPOSITE FIRST AND TOTAL MACE REDUCTIONS OF 30% AND 29%, RESPECTIVELY.AMARIN CORPORATION PLC - REDUCTIONS ALSO OBSERVED IN POST HOC EXPLORATORY ANALYSES OF OTHER COMPOSITE ENDPOINTS.

Amarin Reports Q1 2020 Financial Results

April 30 (Reuters) - Amarin Corporation PLC <AMRN.O>::AMARIN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q1 REVENUE $155 MILLION VERSUS REFINITIV IBES ESTIMATE OF $137.4 MILLION.Q1 GAAP LOSS PER SHARE $0.06.Q1 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.QTRLY ADJUSTED LOSS PER SHARE $0.03.

Amarin Corp PLC Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

Feb 26 (Reuters) - Amarin Corporation PLC <AMRN.O>::AMARIN CORPORATION PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Amarin Corp Qtrly Shr $0.02

Feb 25 (Reuters) - Amarin Corp::QTRLY SHR $0.02; QTRLY ADJ. SHR $0.04; QTRLY NET REV $143.3 MLN, UP 85%.REAFFIRMS FY 2020 GUIDANCE FOR NET REV, OPER. EXPENSES AND INVENTORY INCREASES.AMARIN SAYS MANAGED CARE COVERAGE, WHICH REMAINS DYNAMIC, HAS IMPROVED OVERALL FOR VASCEPA IN 2020.GROWTH IN QTRLY U.S. NET PRODUCT REV DRIVEN BY HIGHER VOLUME OF VASCEPA SALES SUPPORTED BY INCREASED PRESCRIPTION LEVELS.BELIEVES CASH, CASH EQUIVALENTS, NET ACCOUNTS RECEIVABLE, INVENTORY AS OF DEC. 31 ADEQUATE TO ACHIEVE CASH FLOW POSITIVITY FROM VASCEPA.

Amarin Sees 2020 Revenue $650 Million To $700 Million

Jan 7 (Reuters) - Amarin Corporation PLC <AMRN.O>::AMARIN PROVIDES UPDATE TO PRELIMINARY 2019 RESULTS AND FURTHER DETAILS ON 2020 OUTLOOK.SEES FY 2020 REVENUE $650 MILLION TO $700 MILLION.U.S. SALES FORCE EXPANSION ON-TRACK FOR DOUBLING TO 800 SALES PROFESSIONALS IN EARLY 2020.GUIDANCE REMAINS UNCHANGED FROM TOTAL NET REVENUE GUIDANCE ISSUED BY COMPANY ON DECEMBER 13, 2019.AMARIN CORPORATION - 2019 NET TOTAL REVENUE ARE EXPECTED TO BE AT OR POTENTIALLY SLIGHTLY ABOVE UPPER-END OF COMPANY'S PREVIOUSLY EXPRESSED GUIDANCE.AMARIN CORPORATION - FULL-YEAR 2020 NET TOTAL REVENUE GUIDANCE REITERATED AT $650 TO $700 MILLION, PREDOMINATELY FROM U.S. SALES OF VASCEPA.FY2020 REVENUE VIEW $687.5 MILLION -- REFINITIV IBES DATA.AMARIN CORPORATION - ANTICIPATES STARTING 2020 WITH NET CASH OUTFLOWS.AMARIN CORPORATION - ANTICIPATES OPERATING EXPENSES IN 2020 TO INCREASE ABOUT $200 TO $250 MILLION OVER 2019 LEVELS.AMARIN CORPORATION - IN 2020, INTENDS TO SPEND ABOUT $250 MILLION ON INVENTORY PURCHASES.

FDA Says Approval Of Vascepa Was Granted To Amarin Pharma

Dec 13 (Reuters) - FDA::FDA - APPROVES USE OF DRUG TO REDUCE RISK OF CARDIOVASCULAR EVENTS IN CERTAIN ADULT PATIENT GROUPS.FDA - APPROVAL OF VASCEPA WAS GRANTED TO AMARIN PHARMA INC.FDA - APPROVED VASCEPA AS SECONDARY THERAPY TO LOWER CARDIOVASCULAR RISK EVENTS AMONG ADULTS WITH ELEVATED TRIGLYCERIDE LEVELS OF 150 MG/DECILITER OR MORE.

Amarin Receives FDA Approval Of Vascepa To Reduce Cardiovascular Risk

Dec 13 (Reuters) - Amarin Corporation PLC <AMRN.O>::AMARIN RECEIVES FDA APPROVAL OF VASCEPA® (ICOSAPENT ETHYL) TO REDUCE CARDIOVASCULAR RISK.AMARIN - VASCEPA TOTAL NET REVENUE GUIDANCE INCREASED FOR 2019 TO A RANGE OF $410 TO $425 MILLION.AMARIN - VASCEPA TOTAL NET REVENUE GUIDANCE FOR 2020 IS NEWLY GUIDED TO A PROJECTED RANGE OF $650 TO $700 MILLION.AMARIN - REAFFIRMED ITS INTENTION TO PROMPTLY LAUNCH VASCEPA IN U.S..AMARIN - ON TRACK TO DOUBLE SIZE OF SALES FORCE TO A TOTAL OF 800 SALES REPRESENTATIVES NEAR BEGINNING OF 2020.AMARIN - NOT PROVIDING GUIDANCE REGARDING ANNUAL REVENUE LEVELS BEYOND 2020.FY2019 REVENUE VIEW $410.2 MILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $654.5 MILLION -- REFINITIV IBES DATA.

Amarin Says Reduce-It USA Results Showed Robust Cardiovascular Risk Reductions Across A Variety Of Study Endpoints

Nov 11 (Reuters) - Amarin Corporation PLC <AMRN.O>::REDUCE-IT® USA RESULTS, IN PRESPECIFIED SUBGROUP ANALYSES OF LANDMARK REDUCE-IT GLOBAL STUDY, SHOWED ROBUST CARDIOVASCULAR RISK REDUCTIONS ACROSS A VARIETY OF STUDY ENDPOINTS, INCLUDING CARDIOVASCULAR DEATH AND ALL-CAUSE MORTALITY.AMARIN CORPORATION PLC - SIGNIFICANT REDUCTIONS SHOWN IN ALL PREDEFINED COMPOSITE AND INDIVIDUAL CARDIOVASCULAR ENDPOINTS.AMARIN CORPORATION PLC - TOLERABILITY AND SAFETY FINDINGS CONSISTENT WITH FULL STUDY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up